Belzutifan vs Everolimus: Q-TWiST Analysis for ccRCC Progression
Belzutifan Demonstrates Superior quality-Adjusted Time Without Symptoms or Toxicity in Heavily Pretreated Advanced Renal Cell Carcinoma
Table of Contents
Boston, MA – At the 2025 Kidney Cancer Research Summit (KCRS), new data from the LITESPARK-005 study highlighted the meaningful benefits of belzutifan over everolimus in patients with heavily pretreated advanced clear cell renal cell carcinoma (ccRCC).A key analysis focused on Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST), revealing a notable advantage for belzutifan in terms of patient well-being and disease control.
Understanding Q-TWiST: A deeper Look at Patient Outcomes
The Q-TWiST analysis, presented by Professor Thomas Powles, a leading figure in genitourinary oncology, aims to provide a more comprehensive assessment of treatment efficacy than traditional progression-free survival (PFS) alone. While PFS measures the duration a patient lives without their cancer progressing, it doesn’t account for the quality of that time. Q-TWiST addresses this by incorporating both the time patients are free from progression and the absence of significant treatment-related toxicity, further refined by quality-of-life (QoL) data.
“PFS just looks at progression and looks at the area of patients that are progression-free, which is great, but if all that time was spent with significant toxicity, that means less than if a patient has the same amount of time without progression, with no toxicity,” explained Powles. “We can construct Kaplan-Meier curves, and within those curves we can define specific areas: those areas without progression and toxicity, those areas without progression without toxicity, and those areas after progression. In the Q-TWiST analysis specifically, we look at that time, that period, that area without progression and without toxicity, and then we bring in the quality-of-life questionnaires to work out what, in terms of that area, what the quality of life is during that period. That’s the Q of Q-TWiST.”
This nuanced approach allows for a more holistic understanding of a treatment’s benefit, reflecting not just how long patients live without progression, but also how well they live during that period.
LITESPARK-005: Belzutifan vs.Everolimus in Heavily Pretreated ccRCC
LITESPARK-005 is a pivotal randomized phase 3 study that evaluated belzutifan, a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, against everolimus in patients with advanced ccRCC who had received prior treatments. Belzutifan is known for its generally favorable tolerability profile, with common side effects including anemia, hypoxia, and fatigue. In contrast, VEGF tyrosine kinase inhibitors (TKIs) can be associated with more significant toxicities.
The study demonstrated that belzutifan achieved high response rates and improved PFS compared to everolimus in this heavily pretreated population.While an overall survival advantage was not demonstrated, the distinct toxicity profile and improved overall quality of life associated with belzutifan were significant findings.
Q-TWiST Analysis Reveals Meaningful Gain for Belzutifan
The Q-TWiST analysis performed on the LITESPARK-005 data revealed a substantial relative gain for belzutifan. The analysis calculated the difference in Q-TWiST between belzutifan and everolimus, divided by the mean overall survival for everolimus.This metric showed that belzutifan offered an 11.32% relative gain.
“Essentially, it’s not a surprise that belzutifan outperforms everolimus in this respect,” powles stated. “Significantly, because the time to progression was longer, the area therefore was larger, but also the time without toxicity was longer, and that was clinically meaningful by previous parameters which had been set to perform Q-TWiST analysis.”
This finding underscores the clinical relevance of belzutifan’s tolerability profile, translating into more time spent by patients without the burden of disease progression or significant treatment-related side effects, thereby enhancing their overall quality of life.
Reference:
Powles T, de Velasco G, Choueiri TK, et al. Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of belzutifan versus everolimus in previously treated advanced renal cell carcinoma (RCC): LITESPARK-005 (LS-005). Presented at the 2025 Kidney Cancer Research Summit; July 17-18, 2025; Boston, MA